anonymous
Guest
anonymous
Guest
This is the week we really hear what is going on with the oral and the future of our division.
If we do not hear details and timeliness nor have any in depth sessions around the oral market place then the future of the Covid 19 BU is limited with patent expiring soon.
However, if we hear details & enthusiasm from Kristi Michele & Kevin then the future is long and bright with a competitor coming to the $25 Billion a year Paxlovid.
(Kinda wild that 1 oral competitor has done more sales that entire Global Gilead company combined and in just its 1st year on the market still under EUA with zero sales rep support. )
If we do not hear details and timeliness nor have any in depth sessions around the oral market place then the future of the Covid 19 BU is limited with patent expiring soon.
However, if we hear details & enthusiasm from Kristi Michele & Kevin then the future is long and bright with a competitor coming to the $25 Billion a year Paxlovid.
(Kinda wild that 1 oral competitor has done more sales that entire Global Gilead company combined and in just its 1st year on the market still under EUA with zero sales rep support. )